Skip to content
Medical Learning Institute Inc
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
The Power of Community: Translating Innovations into Care in NHL and HL
Community Collective: Obesity
Obstructive Sleep Apnea Series
Shedding Light on T2D
The Evolution of HCT: NMPD Series
TikToktivity series for LR-MDS
Vaccines in Older Adults Series
A Quick Dose of CE
Contact Us
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
The Power of Community: Translating Innovations into Care in NHL and HL
Community Collective: Obesity
Obstructive Sleep Apnea Series
Shedding Light on T2D
The Evolution of HCT: NMPD Series
TikToktivity series for LR-MDS
Vaccines in Older Adults Series
A Quick Dose of CE
Contact Us
Medical Learning Institute Inc
Main Menu
Home
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Accreditation
Menu Toggle
About MLI Accreditation
Joint Providership Request
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
The Power of Community: Translating Innovations into Care in NHL and HL
Community Collective: Obesity
Obstructive Sleep Apnea Series
Shedding Light on T2D
The Evolution of HCT: NMPD Series
TikToktivity series for LR-MDS
Vaccines in Older Adults Series
A Quick Dose of CE
Contact Us
Coral Gables, FL Pre-Assessment
Please enable JavaScript in your browser to complete this form.
Name
*
First
Last
Email
*
What is your NPI?
1. Which of the following best represents your profession?
A. Nurse practitioner
B. Registered Nurse
C. Other
2. A 68-year-old patient with symptomatic high-risk MF has a platelet count of ≥ 50 x 109/L with anemia and splenomegaly but is not a candidate for a allogeneic transplant. Which of the following treatment options would you discuss as the most appropriate for this patient?
A. Ruxolitinib
B. Fedratinib
C. Momelotinib
D. Splenectomy
E. Unsure
3. Which of the following symptoms from the Myeloproliferative Neoplasm Symptom assessment form would you discuss with your patient through shared decision making to help alleviate burden on quality of life?
A. Bone pain, fever, abdominal discomfort, inactivity
B. Bone pain, fever, abdominal discomfort, depression
C. Bone pain, fever, weight gain, depression
D. Bone pain, fever, weight gain, night sweats
E. Unsure
4. A patient with MF is in clinic for evaluation and tells you that they have experienced cytopenias during the course of the disease and it has had a profound impact on their quality of life. They experienced anemia early in the course of their disease. What may be the primary cause of concern for this patient that you should educate and discuss with them today?
A. Past anemia and current impact on thrombocytopenia
B. Patient may require red blood cell transfusion if anemia becomes symptomatic
C. High leukemic transformation risk
D. Natural history of MF is modified by JAK inhibitors so cytopenias are not concerning
E. Unsure
5. A 59-year-old patient with MF has experienced significant spleen enlargement, symptomatic anemia, thrombocytopenia (platelet count 31 x 109/L) as well as debilitating symptoms such as fatigue, night sweats, and bone pain, which considerably impact his quality of life. You are discussing switching his current treatment to pacritinib. What would you tell him he can likely expect regarding this treatment and his quality of life?
A. Pacritinib is associated with a significant reduction in spleen size
B. Pacritinib is associated with a significant improvement in constitutional symptoms
C. Pacritinib is associated with a reduction of spleen size and significantly improves symptoms
D. Pacritinib is associated with a significant reduction in anemia, thrombocytopenia, and spleen size
E. Unsure
6. How confident are you in monitoring/mitigating treatment-related adverse events of JAK inhibitors?
A. Not at all confident
B. Somewhat confident
C. Confident
D. Highly Confident
Submit
Scroll to Top
